We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Imaxio Announces the First Human Clinical Trial Using its Pro-Immunogenic Technology IMX313, in Tuberculosis

News   Sep 16, 2013

 
Imaxio Announces the First Human Clinical Trial Using its Pro-Immunogenic Technology IMX313, in Tuberculosis
 
 
 

RELATED ARTICLES

Probing Yeast Cells to Understand Cell Misregulation

News

Manipulating yeast with optogenetics and microfluidics to explore the MAP kinase pathway may be key for drug discovery.

READ MORE

Protein Curbs Obesity Through Our Gut Bacteria

News

Scientists from the UNC School of Medicine discovered that the anti-inflammatory protein NLRP12 normally helps protect mice against obesity and insulin resistance when they are fed a high-fat diet. The researchers also reported that the NLRP12 gene is underactive in people who are obese, making it a potential therapeutic target for treating obesity and diabetes.

READ MORE

Additional Evidence Shows HPV Vaccine is Safe

News

Further evidence has been generated to demonstrate the safety of the life-saving bivalent HPV vaccine.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE